Контроль болю в онкології Адаптована клінічна настанова, заснована на доказах
|
|
Скачать 2.42 Mb.
|
|
ISCI Оцінка і ведення хронічного болю, листопад 2009 р. Список літератури, представлений в прототипі клінічної настанови sign |
|
*Максимальна добова доза опіоїдів для первинної ланки медичної допомоги ^
*Більш високі дози потребують ретельної реєстрації і можуть вказувати на необхідність консультації спеціаліста з болю. Джерело: Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J of Pain 2009;10:113-30. (Class M) ^ 106 Контроль болю у дорослих з раком: Національна клінічна настанова 1. Portenoy R. Cancer pain. Epidemiology and symptoms. Cancer 1989;63(11 Suppl):2298-307. 2. Stjernsward J, Colleau S, Ventafridda V. The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. J Pain Symptom Manage 1996;12(2):65-72. 3. Z ech D, Grond S, Lynch J, Hertel D, Lehmann K. Validation of World Health Organization guidelines for cancer pain relief: a 10-year prospective study. Pain 1995;63(1):65-76. 4. Larue F, Colleau S, Brasseur L, Cleeland C. Multicentre study of cancer pain and its treatment in France. BMJ 1995;310(6986):1034-7. 5. Cascinu S, Giordani P, Agostinelli R, Gasparini G, Barni S, Beretta G, et al. Pain and its treatment in hospitalised patients with metastatic cancer. Support Care Cancer 2003;11(9):587-92. 6. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain 1986(Suppl 3):S1-226. 7. Melzack R, Wall P. The challenge of pain. 2nd ed. London: Penguin; 1996. 8. McCaffery M. Nursing the patient in pain. London: Harper & Row; 1983. 9. Portenoy R, Hagen N. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41(3):273-81. 10. Guidelines of chaplaincy and spiritual care in the NHS in Scotland. Edinburgh: Scottish Executive Health Department; 2002. (NHS HDL [2002] 76). Available from url: http://www.show.scot.nhs.uk/sehd/mels/HDL2002_76.pdf 11. Distress Management. 3rd ed. Fort Washington: National Comprehensive Cancer Network. Practice Guidelines in Oncology; 2008. 12. E uropean Medicines Agency. Public statement: European Medicines Agency announces regulatory action on COX-2 inhibitors (EMEA/62838/2005). Available from http://www.emea.europa.eu/pdfs/human/press/pr/6275705en.pdf : [Accessed. 11 June. 2007 .] 13. Twycross R, Wilcock A. Palliative care formulary. 3rd ed. London: Palliativedrugs.com; 2007. 14. Moore RJ, Chamberlain RM, Khuri FR. Communicating suffering in primary stage head and neck cancer. Eur J Cancer Care 2004;13(1):53-64. 15. Bostrom B, Sandh M, Lundberg D, Fridlund B. Cancer-related pain in palliative care: patients’ perceptions of pain management. J Adv Nurs 2004;45(4):410-9. 16. McLoughlin PA. Community specialist palliative care: experiences of patients and carers. Int J Palliat Nurs 2002;8(7):344-53. 17. Kimberlin C, Brushwood D, Allen W, Radson E, Wilson D. Cancer patient and caregiver experiences: communication and pain management issues. J Pain Symptom Manage 2004;28(6):566-78. 18. Y ates P, Aranda S, Edwards H, Nash R, Skerman H, McCarthy A. Family caregivers’ experiences and involvement with cancer pain management. J Palliat Care 2004;20(4):287-96. 19. Schumacher KL, Koresawa S, West C, Dodd M, Paul SM, Tripathy D, et al. The usefulness of a daily pain management diary for outpatients with cancer-related pain. Oncol Nurs Forum 2002;29(9):1304-13. 20. Coward DD, Wilkie DJ. Metastatic bone pain: meanings associated with self-report and self-management decision making. Cancer Nurs 2000;23(2):101-8. 21. Cohen MZ, Williams L, Knight P, Snider J, Hanzik K, Fisch MJ. Symptom masquerade: Understanding the meaning of symptoms. Support Care Cancer 2004;12(3):184-90. 22. Berry DL, Wilkie DJ, Thomas Jr CR, Fortner P. Clinicians communicating with patients experiencing cancer pain. Cancer Invest 2003;21(3):374-81. 23. Rogers MS, Todd CJ. The ‘right kind’ of pain: Talking about symptoms in outpatient oncology consultations. Palliat Med 2000;14(4):299-307. 24. V allerand A, Anthony M, MM S. Home care nurses’ perceptions of control over cancer pain. Home Healthcare Nurse 2005;23(10):647-54. 25. McGrath P. Creating a language for ‘spiritual pain’ through research: a beginning. Support Care Cancer 2002;10(8):637-46. 26. Moore RJ, Chamberlain RM, Khuri FR. A voice that wraps around the body - Communication problems in the advanced stages of non-small cell lung cancer. Yale J Biol Med 2001;74(6):367-82. 27. Duggleby W. Enduring suffering: a grounded theory analysis of the pain experience of elderly hospice patients with cancer. Oncol Nurs Forum 2000;27(5):825-31. 28. Carline JD, Curtis JR, Wenrich MD, Shannon SE, Ambrozy DM, Ramsey PG. Physicians’ interactions with health care teams and systems in the care of dying patients: perspectives of dying patients, family members, and health care professionals. J Pain Symptom Manage 2003;25(1):19-28. 29. Wells N, Hepworth JT, Murphy BA, Wujcik D, Johnson R. Improving cancer pain management through patient and family education. J Pain Symptom Manage 2003;25(4):344-56. 30. Wenrich MD, Curtis JR, Ambrozy DA, Carline JD, Shannon SE, Ramsey PG. Dying patients’ need for emotional support and personalized care from physicians: Perspectives of patients with terminal illness, families, and health care providers. J Pain Symptom Manage 2003;25(3):236-46. 31. Breitbart W, Payne D. Pain. In: Holland J, editor. Psychooncology. New York: OUP; 1998. p.450-67. 32. Morley S, Eccleston C, Williams A. Systematic review and metaanalysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain 1999;80(1-2):1-13. 33. Graves KD. Social cognitive theory and cancer patients’ quality of life: a meta-analysis of psychosocial intervention components. Health Psychol 2003;22(2):210-9. 34. Williams S, Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Canc 2006;94:372-90. 35. Spiegel D, Sands S, Koopman C. Pain and depression in patients with cancer. Cancer 1994;74(9):2570-8. 36. Passik S, Dugan W, McDonald M, Rosenfeld B, Theobald D, Edgerton S. Oncologists’ recognition of depression in their patients with cancer. J Clin Oncol 1998;16(4):1594-600. 37. Z aza C, Baine N. Cancer pain and psychosocial factors: a critical review of the literature. J Pain Symptom Manage 2002;24(5):526-42. 38. Sullivan M, Bishop S, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess 1995;7(4):524-32. 39. Buck R, Morley S. A daily process design study of attentional pain control strategies in the self-management of cancer pain. Eur J Pain 2006. 40. Sullivan M, Thorn B, Haythornthwaite J, Keefe F, Martin M, Bradley L, et al. Theoretical perspectives on the relationship between catastrophising and pain. Clin J Pain 2001;17(1):52-64. 41. Tatrow K, Montgomery GH. Cognitive behavioral therapy techniques for distress and pain in breast cancer patients: a metaanalysis. J Behav Med 2006;29(1):17-27. 42. Keefe F, Ahles T, Sutton L, Dalton J, Baucom D, Pope M, et al. Partner-guided cancer pain management at the end of life: a preliminary study. J Pain Symptom Manage 2005;29(3):263-72. 43. Kroenke K, Shen J, Oxman TE, Williams Jr JW, Dietrich AJ. Impact of pain on the outcomes of depression treatment: results from the RESPECT trial Pain 2007;134(1-2):209-15. 44. Du Pen S, Du Pen A, Polissar N, Hansberry J, Kraybill B, Stillman M, et al. Implementing guidelines for cancer pain management: results of a randomized controlled clinical trial. J Clin Oncol 1999;17(1):361-70. 45. Lai Y, Keefe FJ, Sun W, Tsai L, Cheng P, Chiou J, et al. Relationship between pain-specific beliefs and adherence to analgesic regimens in Taiwanese cancer patients: a preliminary study. J Pain Symptom Manage 2002;24(4):415-23. 46. E rsek M, Kraybill BM, Du Pen A. Factors hindering patients’ use of medications for cancer pain. Cancer Pract 1999;7(5):226-32. 47. Ward S, Carlson-Dakes K, Hughes S, Kwekkeboom K, Donovan H. The impact on quality of life of patient-related barriers to pain management. Res Nurs Health 1998;21(5):405-13. 48. E llis P, Robinson P, Ciliska D, Armour T, Brouwers M, O’Brien MA, et al. A systematic review of studies evaluating diffusion and dissemination of selected cancer control interventions. Health Psychol 2005;24(5):488-500. 49. Patiraki E, Papathanassoglou E, Tafas C, Akarepi V, Katsaragakis S, Kampitsi A, et al. A randomized controlled trial of an educational intervention on Hellenic nursing staff’s knowledge and attitudes on cancer pain management. Eur J Oncol Nurs 2006;10(5):337-52. 50. Devine EC. Meta-analysis of the effect of psychoeducational interventions on pain in adults with cancer. Oncol Nurs Forum 2003;30(1):75-89. 51. Chang MC, Chang YC, Chiou JF, Tsou TS, Lin CC. Overcoming patient-related barriers to cancer pain management for home care patients. A pilot study. Cancer Nurs 2002;25(6):470-6. 52. Lin CC, Chou PL, Wu SL, Chang YC, Lai YL. Long-term effectiveness of a patient and family pain education program on overcoming barriers to management of cancer pain. Pain 2006;122(3):271-81. 53. Miaskowski C, Dodd M, West C, Paul SM, Schumacher K, Tripathy D, et al. The use of a responder analysis to identify differences in patient outcomes following a self-care intervention to improve cancer pain management. Pain 2007;129(1-2):55-63. 54. Sela RA, Bruera E, Conner-Spady B, Cumming C, Walker C. Sensory and affective dimensions of advanced cancer pain. Psychooncology 2002;11(1):23-34. 55. Twycross R, Harcourt J, Bergl S. A survey of pain in patients with advanced cancer. J Pain Symptom Manage 1996;12(5):273-82. 56. Serlin R, Mendoza T, Nakamura Y, Edwards K, Cleeland C. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61(2):277-84. 57. O’Boyle CA, Moriarty MJ, Hillard N. Clinical and psychological aspects of cancer-related pain. Irish J Psychol Med 1988;5(2):89-92. 58. Cleeland CS, Nakamura Y, Mendoza TR, Edwards KR. Dimensions of the impact of cancer pain in a four country sample: New information from multidimensional scaling. Pain 1996;67(2-3):267-73. 59. Twycross R, Lack S. Symptom control in far advanced cancer: pain relief London: Pitman; 1983. 60. Derrickson B. The spiritual work of the dying: a framework and case studies. Hosp J 1996; 11(2): 11-30. 61. Kearney M. Mortally wounded: stories of soul pain, death and healing. Dublin: Marino; 1996. 62. Mitchell D. Health care chaplains’ understanding and practice of spiritual care [unpublished thesis]. Glasgow: Glasgow University. Faculty of Medicine; 1998 63. Tittle MB, McMillan SC, Hagan S. Validating the Brief Pain Inventory for use with surgical patients with cancer. Oncol Nurs Forum 2003;30(2 part 1):325-30. 64. Cherny N, Coyle N, Foley K. Suffering in the advanced cancer patient: a definition and taxonomy. J Palliat Care 1994;10(2):57-70. 65. Clinical states: cancer pain. In: McMahon S, Koltzenburg M, editors. Wall and Melzacks’ textbook of pain. 5th ed. New York: Churchill Livingstone; 2006. p.1089-131. 66. Payne R. Cancer pain. Anatomy, physiology, and pharmacology. Cancer Pain 1989;63(11 Suppl):2266-74. 67. Boureau F, Doubrere J, Luu M. Study of verbal description in neuropathic pain. Pain 1990;42(2):145-52. 68. Tearnan B, Cleeland C. Unaided use of pain descriptors by patients with cancer pain. Pain 1990;5(4):228-32. 69. Grond S, Zech D, Diefenbach C, Radbruch L, Lehmann K. Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain 1996;64(1):107-14. 70. Twycross R. Symptom management in advanced cancer 2nd ed. London: Pitman; 1997. 71. Grossman S, Sheidler V, Swedeen K, Mucenski J, Piantadosi S. Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manage 1991;6(2):53-7. 72. Field L. Are nurses still underestimating patients’ pain postoperatively? Br J Nurs 1996; 5(13): 778-84. 73. E lliott B, Elliott T, Murray D, Braun B, Johnson K. Patients and family members: the role of knowledge and attitudes in cancer pain. J Pain Symptom Manage 1996;12(4):209-20. 74. Cleeland C, Gonin R, Hatfield A, Edmonson J, Blum R, Stewart J, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330(9):592-6. 75. Boisvert M, Cohen S. Opioid use in advanced malignant disease: why do different centers use vastly different doses? A plea for standardized reporting. J Pain Symptom Manage 1995;10(8):632-8. 76. de Wit R, van Dam F, Abu-Saad HH, Loonstra S, Zandbelt L, van Buuren A, et al. Empirical comparison of commonly used measures to evaluate pain treatment in cancer patients with chronic pain. J Clin Oncol 1999;17(4):1280-7. 77. Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, et al. Pain measurement tools and methods in clinical research in palliative care: recommendations of an expert working group of the European Association of Palliative Care. J Pain Symptom Manage 2002;23(3):239-55. 78. Wallenstein S, Heidrich Gr, Kaiko R, Houde R. Clinical evaluation of mild analgesics: the measurement of clinical pain. Br J Clin Pharmacol 1980;10(Suppl 2):319-27S. 79. Littman G, Walker B, Schneider B. Reassessment of verbal and visual analog ratings in analgesic studies. Clin Pharmacol Therap 1985;38(1):16-23. 80. Mystakidou K, Parpa E, Tsilika E, Kalaidopoulou O, Georgaki S, Galanos A, et al. Greek McGill pain questionnaire: Validation and utility in cancer patients. J Pain Symptom Manage 2002; 24 (4): 379-87. 81. Caraceni A, Mendoza T, Mencaglia E, Baratella C, Edwards K, Forjaz M, et al. A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). Pain 1996;65(1):87-92. 82. Fainsinger RL, Nekolaichuk CL, Lawlor PG, Neumann CM, Hanson J, Vigano A. A Multicenter Study of the Revised Edmonton Staging System for Classifying Cancer Pain in Advanced Cancer Patients. J Pain Symptom Manage 2005;29(3):224-37. 83. Pautex S, Herrmann F, Le Lous P, Fabjan M, Michel J, Gold G. Feasibility and reliability of four pain self-assessment scales and correlation with an observational rating scale in hospitalized elderly demented patients. J Gerontol Ser A: Biol Sci Med Sci 2005;60(4):524-9. 84. Z wakhalen SM, Hamers JP, Abu-Saad HH, Berger MP. Pain in elderly people with severe dementia: a systematic review of behavioural pain assessment tools. BMC Geriatr 2006;6:3. 85. Simons W, Malabar R. Assessing pain in elderly patients who cannot respond verbally. J Adv Nurs 1995;22(4):663-9. 86. de Rond M, de Wit R, van Dam F, van Campen B, den Hartog Y, Klievink R, et al. Daily pain assessment: value for nurses and patients. J Adv Nurs 1999;29(2):436-44. 87. de Wi tR, van Dam F, Zandbelt L, van Buuren A, van der Heijden K, Leenhouts G, et al. A pain education program for chronic cancer pain patients: follow-up results from a randomized controlled trial. Pain 1997;73(1):55-69. 88. Martindale : the extra pharmacopoeia 31st ed. London: Royal Pharmaceutical Society; 1996. 89. Mercadante S, Fulfaro F. World Health Organization guidelines for cancer pain: a reappraisal. Ann Oncol 2005;16(Suppl 4):iv132-5. 90. V entafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer 1987;59(4):850-6. 91. J adad A, Browman G. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 1995;274(23):1870-3. 92. V entafridda V, Stjernsward J. Pain control and the World Health Organization analgesic ladder. JAMA 1996;275(11):835-6. 93. Twycross R, Lickiss N. Pain control and the World Health Organization analgesic ladder. JAMA 1996;275(11):835. 94. McNicol E, Strassels S, Goudas L, Lau J, Carr D. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain (Cochrane Review). In The Cochrane Library Issue 1, 2006. Chichester; John Wiley. 95. Grond S, Radbruch L, Meuser T, Loick G, Sabatowski R, Lehmann KA. High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage 1999;18(3):174-9. 96. Mystakidou K, Parpa E, Tsilika E, Katsouda E, Kouloulias V, Kouvaris J, et al. Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers. J Pain 2004;5(2):119-32. 97. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev 2006;32(4):304-15. 98. V ielvoye-Kerkmeer A, Mattern C, Uitendaal M. Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. J Pain Symptom Manage 2000;19(3):185-92. 99. Maltoni M, Scarpi E, Modonesi C, Passardi A, Calpona S, Turriziani A, et al. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer 2005;13(11):888-94. 100. Marinangeli F, Ciccozzi A, Leonardis M, Aloisio L, Mazzei A, Paladini A, et al. Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 2004;27(5):409-16. 101. Davis MP. Management of cancer pain: Focus on new opioid formulations. Am J Cancer 2006;5(3):171-82. 102. Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain 1997;72(1-2):95-7. 103. Dellemijn P, Vanneste J. Randomised double-blind active-placebocontrolled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 1997;349(9054):753-8. 104. Cherny N, Thaler H, Friedlander-Klar H, Lapin J, Foley K, Houde R, et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies. Neurology 1994;44(5):857-61. 105. J oint Formulary Committee. British National Formulary. 55th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2007. 106. Stockler M, Vardy J, Pillai A, Warr D. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 2004;22(16):3389-94. 107. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers (Cochrane Review). In The Cochrane Library Issue 2, 2007. Chichester; John Wiley. 108. Silverstein F, Graham D, Senior J, Davies H, Struthers B, Bittman R, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebocontrolled trial. Ann Int Med 1995;123(4):241-9. 109. García Rodríguez L, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343(8900):769-72. 110. Cardiovascular and gastrointestinal safety of NSAIDs. MeReC 2007; 111. Cardiovascular safety of NSAIDs and selective COX-2 inhibitors. Current Problems in Pharmacovigilance 2006; 31: 7. 112. Update on the prescribing of NSAIDS. MeReC Monthly 2008; 113. Wong J, Wiffen P. Bisphosphonates for the relief of pain secondary to bone metastases (Cochrane Review). In The Cochrane Library Issue 1, 2006. Chichester; John Wiley. 114. Carr DB, Goudas LC, Balk EM, Bloch R, Ioannidis JP, Lau J. Evidence report on the treatment of pain in cancer patients. J Natl Cancer Inst Monogr 2004;32:23-31. 115. McQuay HJ, Collins SL, Carroll D, Moore RA. Radiotherapy for the palliation of painful bone metastases (Cochrane Review). In The Cochrane Library Issue 2, 2000. Chichester; John Wiley. 116. Pecherstorfer M, Rivkin S, Body JJ , Diel I, Bergström B. Longterm safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig 2006;26(6):315-22. 117. Scottish Intercollegiate Guidelines Network. SIGN 84: Management of breast cancer in women, A national clincal guideline. Edinburgh: SIGN; 2005. 118. Bamias A, Kastritis E, Bamia C, Moulopoulos L, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23(34):8580-7. 119. Ott S. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90(3):1897-9. 120. Woo S, Hellstein J, Kalmar J. Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Int Med 2006;145(10):753-61. 121. Saarto T, Wiffen P. Antidepressants for neuropathic pain (Cochrane Review). In The Cochrane Library Issue 3, 2007. 122. Forssell H, Tasmuth T, Tenovuo O, Hampf G, Kalso E. Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. J Orofac Pain 2004;18(2):131-7. 123. Sindrup S, Bach F, Madsen C, Gram L, Jensen T. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. . Neurology 2003;60(8):1284-9. 124. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S, Wernicke JF, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Pain 2005;116(1-2):109-18. 125. Wernicke JF, Pritchett YL, D’Souza DN, Waninger A, Tran P, Iyengar S, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67(8):1411-20. 126. Wiffen P, McQuay H, Edwards J, Moore R. Gabapentin for acute and chronic pain (Cochrane Review). In The Cochrane Library Issue 1, 2006. Chichester; John Wiley. 127. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain (Cochrane Review). In The Cochrane Library Issue 2, 2006. Chichester; John Wiley. 128. Siddall P, Cousins M, Otte A, Griesing T, Chambers R, Murphy T. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006;67(10):1792-800. 129. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352(13):1324-34. 130. Bell, Eccleston, Kalso. Ketamine as an adjuvant to opioids for cancer pain (Cochrane Review). In The Cochrane Library Issue 1, 2006. Chichester; John Wiley. 131. Y ang C, Wong C, Chang J, Ho S. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can J Anesthes 1995;443(4):379-83. 132. Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: A randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000;20(4):246-52. 133. Cerchietti LC, Navigante AH, Korte MW, Cohen AM, Quiroga PN, Villaamil EC, et al. Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study. Pain 2003;105(1-2):265-73. 134. Z eppetella G, Paul J, Ribeiro MDC. Analgesic efficacy of morphine applied topically to painful ulcers. J Pain Symptom Manage 2003;25(6):555-8. 135. Ribeiro MDC, Joel SP, Zeppetella G. The bioavailability of morphine applied topically to cutaneous ulcers. J Pain Symptom Manage 2004;27(5):434-9. 136. Flock P. Pilot study to determine the effectiveness of diamorphine gel to control pressure ulcer pain. J Pain Symptom Manage 2003;25(6):547-54. 137. Gammaitoni AR, Alvarez NA, BS G. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. J Clin Pharmacol 2003;43(2):111-7. 138. Meier T, Wasner G, Faust M, Kuntzer T, Ochsner F, Hueppe M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, doubleblind, placebo-controlled study. Pain 2003;106(1-2):151-8. 139. Galer B, Jensen M, Ma T, Davies P, Rowbotham M. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain 2002;18(5):297-301. 140. Mason L, Moore R, Derry S, Edwards J, McQuay H. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004;328(7446):991. 141. Campbell FA, Tramer MR, Carroll D, Reynolds DJM, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001;323(7303):13-6. 142. Noyes RJ, Brunk S, Avery D, Canter A. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Therap 1975;18(1):84-9. 143. Abrams D, Jay C, Shade S, Vizoso H, Reda H, Press S, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007;68(7):515-21. 144. Rog D, Nurmikko T, Friede T, Young C. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65(6):812-9. 145. Myers KG, Trotman IF. Use of ketorolac by continuous subcutaneous infusion for the control of cancer-related pain. Postgrad Med J 1994;70(823):359-62. 146. Regnard C. A guide to symptom relief in palliative care. 5th ed. Abingdon: Radcliffe Medical; 2004. 147. Williams J. Palliative care prescribing. Drug Information Letter No117 2001; 2008: 148. Q uiding H, Persson G, Ahlström U, Bångens S, Hellem S, Johansson G, et al. Paracetamol plus supplementary doses of codeine. An analgesic study of repeated doses. Eur J Clin Pharmacol 1982;23(4):31-9. 149. Chary S, Goughnour B, Moulin D, Thorpe W, Harsanyi Z, Darke A. The dose-response relationship of controlled-release codeine (Codeine Contin) in chronic cancer pain. [Abstract]. J Pain Symptom Manage 1994;9(6):363-71. 150. Lurcott G. The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone. Anesthesia Progress 1998;45(4):154–6. 151. Leppert W. Analgesic efficacy and side effects of oral tramadol and morphine administered orally in the treatment of cancer pain. Nowotwory 2001;51(3):257-66. 152. Petzke F, Radbruch L, Sabatowski R, Karthaus M, Mertens A. Slowrelease tramadol for treatment of chronic malignant pain--an open multicenter trial. Support Care Cancer 2001;9(1):48-54. 153. Welsh J, Reid A, Graham J, Curto J, MacLeod K, O’Neill C. Physicians’ knowledge of transdermal fentanyl. Palliat Med 2005;19(1):9-16. 154. Barclay S, Todd C, Grande G, Lipscombe J. Controlling cancer pain in primary care: the prescribing habits and knowledge base of general practitioners. J Pain Symptom Manage 2002;23(5):383-92. 155. Building a safer NHS for patients: improving medication safety. Available from http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4084961.pdf: [Accessed. 24 Sept. 2008.] 156. Hanks G, Conno F, Cherny N, Hanna M, Kalso E, McQuay H, et al. Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Canc 2001;84(5):587-93. 157. Ross J, Riley J, Quigley C, KI. W. Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist 2006;11(7):765-73. 158. Martindale W. Martindale: the complete drug reference. 35th. London: Pharmaceutical Press; 2007. 159. Diamorphine hydrochloride. In: Dollery C, editor. Therapeutic drugs. London: Churchill Livingstone; 1991. p.D74. 160. Freynhagen R, von Giesen HJ, Busche P, Sabatowski R, Konrad C, Grond S. Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients with chronic pain. J Pain Symptom Manage 2005;30(3):289-97. 161. Marier J, Lor M, Potvin D, Dimarco M, Morelli G, Saedder E. Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. J Clin Pharmacol 2006;46(6):642-53. 162. Morphine in cancer pain: modes of administration. Expert Working Group of the European Association for Palliative Care. BMJ 1996;312(7034):823-6. 163. McQuay H, Moore A. Bibliography and systematic reviews in cancer pain. A report to the NHS National Cancer Research and Development Programme London: Department of Health; 1997. 164. Portenoy R. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999;79(2-3):303-12. 165. Säwe J, Dahlström B, Rane A. Steady-state kinetics and analgesic effect of oral morphine in cancer patients. Eur J Clin Pharmacol 1983;24(4):537-42. 166. Farrar J, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst Monogr 1998;90(8):611-6. 167. Christie JM. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998;16(10):3238-45. 168. Coluzzi PH, et al Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immedidate release (MSIR). Pain 2001;91(1-2):123-30. 169. Z eppetella G, Ribeiro M. Opioids for the management of breakthrough (episodic) pain in cancer patients (Cochrane Review). In The Cochrane Library Issue 1, 2006. Chichester; John Wiley. 170. The European Association for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of bioequivalence and bioavailability. Available from http://www.emea.europa.eu/pdfs/ human/ewp/140198en.pdf: [Accessed. 24 Sept. 2008.] 171. Wiffen P, Edwards J, McQuay H. Oral morphine for cancer pain (Cochrane Review). In The Cochrane Library Issue 1, 2006.Chichester; John Wiley. 172. V idal L, Shavit M, Fraser A, Paul M, Leibovici L. Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ 2005;331(7511):263. 173. J oint Formulary Committee. British National Formulary. 54th ed. . British Medical Association and Royal Pharmaceutical Society of Great Britain 2007. 174. Aronoff G, Berns J, Brier ME, Golper T, Morrison G, Singer I. Drug prescribing in renal failure: dosing guidelines for adults. Philadelphia: American College of Physicians; 1999. 175. Broadbent A, Khor K, Heaney A. Palliation and chronic renal failure: Opioid and other palliative medications - Dosage guidelines. Progr Palliat Care 2003;11(4):183-90. 176. Mercadante S, Arcuri E. Opioids and renal function. J Pain 2004;5(1):2-19. 177. Launay-Vacher V, Karie S, Fau JB, Izzedine H, Deray G. Treatment of pain in patients with renal insufficiency: The World Health Organization three-step ladder adapted. J Pain 2005;6(3):137-48. 178. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004;28(5):497-504. 179. Pauli-Magnus C, Hofmann U, Mikus G, Kuhlmann U, Mettang T. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dialysis Transplant 1999;14(4):903-9. 180. Lee M, Leng M, Tiernan E. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 2001;15(1):26-34. 181. Babul N, Darke A, Hagen N. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage 1995;10(3):184-6. 182. Nelson K, Glare P, Walsh D, ES G. A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. J Pain Symptom Manage 1997;13(5):262-7. 183. Wilcock A, Jacob JK, Charlesworth S, Harris E, Gibbs M, Allsop H. Drugs given by a syringe driver: a prospective multicentre survey of palliative care services in the UK. Palliat Med 2006;20(7):661-4. 184. V ermeire A, Remon JP. Stability and compatibility of morphine. Int J Pharm 1999;187(1):17-51. 185. Warfield CA. Controlled-release morphine tablets in patients with chronic cancer pain: a narrative review of controlled clinical trials. Cancer 1998;82(12):2299-306. 186. O’Brien T, Mortimer P, McDonald C, Miller A. A randomized crossover study comparing the efficacy and tolerability of a novel once-daily morphine preparation (MXL capsules) with MST Continus tablets in cancer patients with severe pain. Palliat Med 1997;11(6):475-82. 187. Kaplan R, Parris W, Citron M, Zhukovsky D, Reder R, Buckley B, et al. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. J Clin Oncol 1998;16(10):3230-7. 188. An open, single dose, four part, randomised crossover study to compare the pharmacokinetics of oxycodone from an oxycodone injection 10mg/ml administered as a subcutaneous, intravenous, or intramuscular bolus dose with an oxycodone normal release oral liquid 5mg/fml in 24 health male volunteers Napp Pharmaceuticals; 200? OXI1202 [unpublished]. 189. Fallon M, O’Neill W. Spinal surgery in the treatment of metastatic back pain: three case reports. Palliat Med 1993;7(3):235-8. 190. Mercadante S. Opioid titration in cancer pain: a critical review. European Jpurnal of Pain 2007;11(8):823-30. 191. Goudas L, Carr D, Bloch R, Balk E, Ioannidis J, Terrin N, et al. Management of Cancer Pain. Rockville, MD: Agency for Healthcare Research and Quality; 2001. AHRQ Publication No. 02-E002. 192. Q uigley C. Opioid switching to improve pain relief and drug tolerability (Cochrane Review). In The Cochrane Library Issue 3, 2004. Chichester; John Wiley. 193. Riley J, Ross JR, Rutter D, Wells AU, Goller K, du Bois R, et al. No pain relief from morphine. Support Care Cancer 2006;14(1):56-64. 194. McMunnigall F, Welsh J. Opioid withdrawal syndrome on switching from hydromorphone to alfentanil. Palliat Med 2008;22(2):191-2. 195. Mercadante S, Ferrera P, Villari P, Casuccio A. Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol 2005;23(22):5229-34. 196. Pereira J, Lawlor P, Vigrano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids: A critical review and proposals for long-term dosing. J Pain Symptom Manage 2001;22(2):672-87. 197. Anderson R, Saiers J, Abram S, Schlicht C. Accuracy in equianalgesic dosing. conversion dilemmas. J Pain Symptom Manage 2001;21(5):397-406. 198. Q uigley C. Hydromorphone for acute and chronic pain (Cochrane Review). In The Cochrane Library Issue 1, 2006. Chichester; John Wiley. 199. Curtis G, Johnson G, Clark P, Taylor R, Brown J, O’Callaghan R, et al. Relative potency of controlled-release oxycodone and controlled release morphine in a postoperative pain model. Eur J Clin Pharmacol 1999;55(6):425-9. 200. Benitez-Rosario MA, Feria M, Salinas-Martin A, Martinez- Castillo LP, Martin-Ortega JJ. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. Cancer 2004;101(12):2866-73. 201. Santiago-Palma J, Khojainova N, Kornick C, Fischberg DJ, Primavera LH, Payne R, et al. Intravenous methadone in the management of chronic cancer pain: Safe and effective starting doses when substituting methadone for fentanyl. Cancer 2001;92(7):1919-25. 202. Scholes C, Gonty N, Trotman I. Methadone titration in opioidresistant cancer pain`. Eur J Cancer Care 1999;8(1):26-9. 203. Moryl N, Santiago-Palma J, Kornick C, Derby S, Fischberg D, Payne R, et al. Pitfalls of opioid rotation: Substituting another opioid for methadone in patients with cancer pain. Pain 2002;96(3):325-8. 204. Patanwala A, Duby J, Waters D, Erstad B. Opioid conversions in acute care. Ann Pharmacother 2007;41(2):255-67. 205. Lehmann K, Zech D. Transdermal fentanyl: clinical pharmacology J Pain Symptom Manage 1992;7(3 suppl):8-16. 206. Miles C, Fellowes D, Goodman M, S. W, Fellowes D, Goodman M, et al. Laxatives for the management of constipation in palliative care patients (Cochrane Review). In The Cochrane Library Issue 4, 2006. Chichester; John Wiley 207. Sykes N. A volunteer model for the comparison of laxatives in opioid-related constipation. J Pain Symptom Manage 1996;11:363-9. 208. Fallon M, Hanks G. Morphine constipation and performance status in advanced cancer patients Palliat Med 1999;13(2):159-60. 209. Soden K, Vincent K, Craske S, Lucas C, Ashley S. A randomized controlled trial of aromatherapy massage in a hospice setting. Palliat Med 2004;18(2):87-92. 210. Fellowes D, Barnes K, Wilkinson S. Aromatherapy and massage for symptom relief in patients with cancer. (Cochrane Review). In The Cochrane Library Issue 4, 2004. Chichester; John Wiley. 211. Post-White J, Kinney M, Savik K, Gau J, Wilcox C, I. L. Therapeutic massage and healing touch improve symptoms in cancer. Integr Cancer Ther 2003;2(4):332-44. 212. Cepeda MS, Carr DB, Lau J, Alvarez H. Music for pain relief (Cochrane Review). In The Cochrane Library Issue 4, 2006.Chichester; John Wiley. 213. Siedliecki S, Good M. Effect of music on power, pain, depression and disability. J Adv Nurs 2006;54(5):553-62. 214. Lee H, Schmidt K, Ernst E. Acupuncture for the relief of cancerrelated pain--a systematic review. Eur J Pain 2005;9(4):437-44. 215. Alimi D, Rubino C, Pichard-Leandri E, Fermand-Brule S, Dubreuil-Lemaire M, Hill C. Analgesic effect of auricular acupuncture for cancer pain: a randomized, blinded, controlled trial J Clin Oncol 2003;21(22):4120-6. 216. Robb KA, Newham DJ, Williams JE . Transcutaneous electrical nerve stimulation vs. transcutaneous spinal electroanalgesia for chronic pain associated with breast cancer treatments. J Pain Symptom Manage 2007;33(4):410-9. 217. Stephenson NLN, Swanson M, Dalton J, Keefe FJ, Engelke M. Partner-delivered reflexology: effects on cancer pain and anxiety. Oncol Nurs Forum 2007;34(1):127-32. 218. Olsen K, Hanson J, Michaud M. A phase II trial of reiki for the management of pain in advanced cancer. J Pain Symptom Manage 2003;26(5):990-7. 219. Syrjala K, Cummings C, Donaldson G. Hypnosis or cognitive behavioral training for the reduction of pain and nausea during cancer treatment: a controlled clinical trial. Pain 1992;48(2):137-46. 220. Rajasekaran M, Edmonds P, Higginson I. Systematic Review of Hypnotherapy for treating symptoms in terminally ill Adult Cancer Patients Palliat Med 2005;19(5):418 - 26. 221. Liossi C. Hypnosis in Cancer Care. Contemp Hypnosis 2006;23(1):47-57. 222. Sze W, Shelley M, Held M. Palliation of Metastatic Bone Pain (Cochrane Review). In The Cochrane Library Issue 1, 2006. Chichester; John Wiley. 223. Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 2007;25(11):1423-36. 224. Kaasa S, Brenne, E., Lund, J. A., Fayers, P., Falkmer, U., Holmberg, M., Lagerlund, M. and Bruland, O. Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy x 1) versus multiple fractions (3 Gy x 10) in the treatment of painful bone metastases. Radiother Oncol 2006;79(3):278-84. 225. Roque M, Martinez-Zapata M, Alonso-Coello P, Catala E, Garcia J, Ferrandiz M. Radioisotopes for metastatic bone pain (CochraneReview). In The Cochrane Library Issue 1, 2006. Chichester; John Wiley. 226. Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S, et al. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Canc Res Treat 2001;66(2):101-9. 227. Leondi AH, Souvatzoglou MA, Rapti AS, Leontopoulou SA, Papadaki EK, Datseris EI, et al. Palliative treatment of painful disseminated bone metastases with 186Rhenium-HEDP in patients with lung cancer. Q J Nucl Med 2004;48(3):211-9. 228. Han SH, de KJM, Tan S, van hSAD, Derksen BH, van DA, et al. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med 2002;43(9):1150-6. 229. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: A systematic review. Lancet Oncol 2005;6(6):392-400. 230. Lieberman I, Reinhardt MK. Vertebroplasty and Kyphoplasty for Osteolytic Vertebral Collapse. Clin Orthopaed Rel Res 2003;415(Suppl):S176-86. 231. Hulme PA, Krebs J, Ferguson SJ, Berlemann U. Vertebroplasty and kyphoplasty: a systematic review of 69 clinical studies. Spine 2006;31(17):1983-2001. 232. Lowe RW, Phillips FM. Percutaneous vertebral augmentation for malignant disease of the spine. Curr Opinion Orthoped 2005;16(6):489-93. 233. Cheung G, Chow E, Holden L, Vidmar M, Danjoux C, Yee AJ, et al. Percutaneous vertebroplasty in patients with intractable pain from osteoporotic or metastatic fractures: A prospective study using quality-of-life assessment. Can Assoc Radiol J 2006;57(1):13-21. 234. Ramos L, De Las Heras JA, Sanchez S, Gonzalez-Porras JR, Gonzalez R, Mateos MV, et al. Medium-term results of percutaneous vertebroplasty in multiple myeloma. Eur J Haematol 2006;77(1):7-13. 235. Barragan-Campos HM, Vallee JN, Lo D, Cormier E, Jean B, Rose M, et al. Percutaneous vertebroplasty for spinal metastases: complications. Radiology 2006;238(1):354-62. 236. Weill A, Kobaiter H, Chiras J. Acetabulum malignancies: technique and impact on pain of percutaneous injection of acrylic surgical cement. Eur Radiol 1998;8(1):123-9. 237. Kelekis A, Lovblad K, Mehdizade A, Somon T, Yilmaz H, Wetzel S, et al. Pelvic osteoplasty in osteolytic metastases: technical approach under fluoroscopic guidance and early clinical results. J Vasc Interven Radiol 2005;16(1):81-8. 238. Marcy P, Palussière J, Descamps B, Magné N, Bondiau P, Ciais C, et al. Percutaneous cementoplasty for pelvic bone metastasis. Support Care Cancer 2000;8(6):500-3. 239. Staats P, Hekmat H, Sauter P, Lillemoe K. The effects of alcohol celiac plexus block, pain and mood on longevity in patients with unresectable pancreatic cancer: A double-blind, randomized, placebo-controlled study. Pain Med 2001;2(1):28-34. 240. Polati E, Finco G, Gottin L, Bassi C, Pederzoli P, Ischia S. Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer. Br J Surg 1998;85(2):199-201. 241. Wong GY, Schroeder DR, Carns PE, Wilson JL, Martin DP, Kinney MO, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004;291(9):1092-9. 242. Süleyman Ozyalçin N, Talu G, Camlica H, Erdine S. Efficacy of coeliac plexus and splanchnic nerve blockades in body and tail located pancreatic cancer pain. Eur J Pain 2004;8(6):539-45. 243. Shulman M, Harris JE, Lubenow TR, Nath HA, Ivankovich AD. Comparison of epidural butamben to celiac plexus neurolytic block for the treatment of the pain of pancreatic cancer. Clin J Pain 2000;16(4):304-9. 244. Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002.;20:4040-9. 245. Dahm P, Lundborg C, Janson M, Olegard C, Nitescu P. Comparison of 0.5% intrathecal bupivacaine with 0.5% intrathecal ropivacaine in the treatment of refractory cancer and noncancer pain conditions: results from a prospective, crossover, double-blind, randomized study. Regional Anesthes Pain Med 2000;25(5):480-7. 246. Ballantyne JC, Carwood CM. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer (Cochrane Review). In The Cochrane Library Issue 1, 2005. Chichester; John Wiley. 247. Fassoulaki A, Sarantopoulos C, Melemeni A, Hogan Q. EMLA reduces acute and chronic pain after breast surgery for cancer. Regional Anesthes Pain Med 2000;25(4):350-5. 248. Fassoulaki A, Triga A, Melemeni A, Sarantopoulos C. Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer. Anesth Analg 2005;101(5):1427-32. 249. Scottish Medicines Consortium. Submission to the Scottish Medicines Consortium. Buprenorphine transdermal patches 5, 10 and 20 microgram/hour 7-day formulation (BuTrans®). [Accessed on 8 Sep 2008]. Available from url: http://www.scottishmedicines. org.uk/smc/files/DAD%20buprenorphine%20patches%20 2nd%20resubmission%20FINAL%20July%202008.doc%20 amended150708.doc%20for%20website.pdf. 250. Scottish Medicines Consortium. Submission to the Scottish Medicines Consortium. Buprenorphine (Transtec®) patch. [Accessed 8 September 2008]. Available from URL: http:// www.scottishmedicines.org.uk/smc/files/buprenorphine%20_Transtec%20matrix%20patch_.pdf. 251. Scottish Medicines Consortium. Submission to the Scottish Medicines Consortium. Fentanyl transdermal patches (Durogesic®).[Accessed on 8 September 2008]. Available from URL: http://www.scottishmedicines.org.uk/smc/files/Durogesic(10-01-03).pdf . 252. Scottish Medicines Consortium. Submission to the Scottish Medicines Consortium. Oxycodone (Oxynorm®) injection. [Accessed on 8 September 2008]. Available from URL: http://www.scottishmedicines.org.uk/smc/files/oxycodone%20_OxyNorm_pdf 253. Scottish Medicines Consortium. Submission to the Scottish Medicines Consortium. Oxycodone prolonged release tablets 5,10,20,40 and 80mg (OxyContin®). [Accessed 8 September 2008]. Available from URL: http://www.scottishmedicines.org . uk/smc/files/oxycodone%20hydrochloride%20_OxyContin_%20_197-05_.pdf. 254. Kelly E. A stability study of diamorphine in combination with metoclopramide, methotrimeprazine, dexamethasone. M.Sc. project, Strathclyde University. [unpublished thesis]. Glasgow: Strathclyde University. 1990 255. Dickman A, Schneider J, Varga J. The syringe driver: Continuous subcutaneous infusions in palliative care 2nd ed. Oxford: Oxford University Press; 2005. 256. Gardiner P. Compatibility of an Injectable Oxycodone Formulation with typical diluents, syringes, infusion bags and drugs for potential co-administration. Hospital Pharmacist 2003;10(8):354 - 61. 257. Grassby PF, Hutchings L. Drug combinations in syringe drivers: the compatibility and stability of diamorphine with cyclizine and haloperidol. Palliat Med 1997;11(3):217-24. 258. Regnard C, Pashley S, Westrope F. Anti-emetic/diamorphine mixture compatibility in infusion pumps. Br J Pharm Pract 1986;8: 218-20. 259. V irdee H. Is diamorphine/ketorolac stable? Pharmacy in Practice 1997;7(2):82-3. 260. Allwood M, Brown P, Lee M. Stability Of Injections Containing Diamorphine and Midazolam in Plastic Syringes InI J Pharm Pract 1994:57-9. 261. Fielding H, Kyaterekera N, Skellern GG, Tettey JN, McDade JR, Msuya Z, et al. The compatibility and stability of octreotide acetate in the presence of diamorphine hydrochloride in polypropylene syringes. Palliat Med 2000;14(3):205-7. 262. Glaxo Wellcome, in house data. 263. Ireland D. Unpublished data from Pharmaceutical Quality Control Laboratory, Countess of Chester Hospital. 264. Sneddon J. Stability study of diamorphine admixtures in plastic syringes using HPLC. 1990; СПИСОК ЛіТЕРАТУРи, використаної В ПРОЦЕСІ АДАПТАЦІЇ клінічної настанови
Д  ні так так ні одаток 5 Короткий опис болю (Коротка форма) ISCI Оцінка і ведення хронічного болю, листопад 2009 р. Дослідження №_______ Лікарня №_________________ _____________________________________________________________________________ Дата____/_____/_____ Час________ ПІП___________________________________________ 1. Впродовж усього життя більшість з нас мали болі (головні, розтягування, зубний біль) Чи у вас був інший біль, за винятком цих болів, які можуть бути щодня? |
Ваша оценка этого документа будет первой.
Ваша оценка:
Похожие:
База данных защищена авторским правом ©MedZnate 2000-2016
allo, dekanat, ansya, kenam
обратиться к администрации | правообладателям | пользователям
allo, dekanat, ansya, kenam
обратиться к администрации | правообладателям | пользователям